Safety and efficacy of macitentan and riociguat upfront combination therapy in patients with idiopathic pulmonary arterial hypertension at intermediate risk.

Back

ESC2025 Premium Access

Safety and efficacy of macitentan and riociguat upfront combination therapy in patients with idiopathic pulmonary arterial hypertension at intermediate risk.

Session: Pulmonary arterial hypertension therapy

Topic: Pharmacotherapy

Speaker: Professor M. D'Alto (Naples, IT)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Professor Michele D'Alto

AORN Ospedali dei Colli - Monaldi Hospital, Naples (Italy)

5 presentations

4 followers

4 more presentations in this session

A real-world study on selexipag for pulmonary arterial hypertension: a single-center retrospective study

Speaker: Doctor R. Asano (Suita, JP)

Could we maintain the initial efficacy of triple sequential combination therapies with selexipag in patients with pulmonary arterial hypertension : Insights from a single-centre study

Speaker: Associate Professor H. Tokgoz (Istanbul, TR)

Efficacy and safety of selexipag based triple combination targeted drug therapy in chinese patients with pulmonary arterial hypertension

Speaker: Doctor X. Cui (Jinan, CN)

Switching sildenafil to riociguat in chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty - the S2R study

Speaker: Doctor T. Kam (Shatin, HK)

Access the full session

Pulmonary arterial hypertension therapy

Speakers: Professor M. D'Alto, Doctor R. Asano, Associate Professor H. Tokgoz, Doctor X. Cui, Doctor T. Kam

Access

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources